J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...

The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

A programme looking to advance the understanding of how cancer develops has been backed with £50 million. Global biopharma company GSK has invested up to £50 million in a collaboration with Oxford ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

With an estimated 2.1 million children in Nigeria and almost one million in Ethiopia1 classed as 'zero dose', having never ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Every year, 21.5 million people are forcibly displaced by floods, droughts, wildfires, and storms. This number is set to rise ...

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.